- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05803811
Effekt av kolon levert vitamin B2 på tarmmikrobiota og relaterte helsebiomarkører hos friske eldre voksne
The goal of this intervention study (clinical trial) is to investigate the effect of colon-delivered Riboflavin (vitamin B2) on the faecal microbial composition and diversity in older healthy subjects (50 -70 years of age)
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Cork, Irland
- Atlantia Food Clinical Trials, 1st Floor, Block C, Heron House, Blackpool Retail Park, Cork
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Participants must be willing and able to give written informed consent and to understand, to participate, and to comply with the clinical study requirements.
- Between 50 and 70 years of age.
- Has a BMI of between 18.5 - 30 Kg/m2.
- Participants have had a stable body weight (≤5 % change) over the past 3-months.
- Is in general good health, as determined by interview and vital signs (blood pressure, heart rate, pulse) by the investigator.
- Willing to avoid consuming gut microbiome modulating dietary supplements, prebiotic, probiotic, or fibre-rich supplements, and, within 4 weeks prior to the baseline visit, until the end of the study.
- Maintain current level of physical activity.
- Willing to consume the investigational product daily for the duration of the study.
- Female participants in menopause for at least the last one year. -
Exclusion Criteria:
-
Are hypersensitive to any of the components of the test product.
-
Has taken antibiotics within the previous 3 months prior to Baseline (Visit2)
-
Is currently using systemic steroids, systemic antibiotics, proton pump inhibitors, H2 blocker, antacid, metformin, or immunosuppressant medication.
-
Participant has a history of drug and/or alcohol abuse at the time of enrolment (Drinks more than nationally recommended units per week (>11 units for women; >17 units for men); Is currently in treatment for alcohol/substance abuse; Has been diagnosed with alcohol/substance abuse disorder).
-
Is a smoker or vaper.
-
Vegetarian or vegan.
-
Has made any major dietary changes in the past 3 months prior to Baseline (Visit 2).
-
Planned major changes in the lifestyle (i.e., diet, dieting, exercise level, significant travel) during the duration of the study.
-
Has a currently active eating disorder.
-
Has food allergies or other issues with foods that would preclude the intake of the study products, as determined by the study investigator.
-
Is having a typical fibre intake >30 g fibre/day.
-
Has an active gastrointestinal disorder or previous gastrointestinal surgery, which in the opinion of the investigator would impact the study outcomes.
-
If taking chronic medications (e.g., anti-hypertensive medications), they must have been taking the product for at least two months to screening and agree to maintain the same dosage throughout the study.
-
Has severe or uncontrolled type 2 diabetes, psychiatric disorder, gastrointestinal disease (i.e., diarrhoea, Crohn's disease, ulcerative colitis, IBS, diverticulosis, stomach or duodenal ulcers respiratory or cardiac illness or any other condition which in the opinion of the investigator would impact the study outcomes.
-
Has a current or history of any gastrointestinal cancer
-
Are severely immunocompromised (HIV positive, transplant patient, on anti-rejection medications, on a steroid for >30 days, or chemotherapy or radiotherapy with the last year).
-
Experiences alarm features such as weight loss, rectal bleeding, a recent change in bowel habit (<3 months).
-
Have a current malignant disease or any concomitant end-stage organ disease.
-
Individuals who, in the opinion of the investigator are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.
-
Participants may not be receiving treatment involving experimental drugs. If the participant has been in a recent experimental trial, these must have been completed not less than 60 days prior to this study.
-
Participants who have undergone intensive skin treatments (e.g. laser treatment or skin related surgery) in the last 3 months.
-
If taking any dietary supplements or medications known to affect skin health or other trial measures (resveratrol, ginkgo biloba, ginseng, fruit powder extracts and DHA).
-
Has a skin condition likely to interfere with skin assessments (e.g., eczema, dermatitis, any open skin wounds, reactive and sensitive skin).
-
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Low dose
Daily dose of 1.4 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Eksperimentell: Mid dose
Daily dose of 10 mg of Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Eksperimentell: high dose
Daily dose of 75 mg Vitamin B2 (Riboflavin) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
|
Placebo komparator: Placebo
One capsule of 570 mg (consisting of microcrystalline cellulose) once a day for 12 weeks |
Colon delivered vitamin B2 (Riboflavin) for 12 weeks |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Faecal microbial composition
Tidsramme: from baseline to 12 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 12 |
from baseline to 12 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Alpha diversity
Tidsramme: from baseline to 12 weeks
|
Alpha diversity (Observed, Chao Index, Simpson Index, Shannon Index) at baseline and week 12. |
from baseline to 12 weeks
|
|
Beta diversity
Tidsramme: week 0 to week 12
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 12 |
week 0 to week 12
|
|
Faecal microbial metabolites fatty acid content at baseline and week 12
Tidsramme: from baseline to 12 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 12 |
from baseline to 12 weeks
|
|
Acetate, Propionate and Butyrate
Tidsramme: baseline and week 12
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 12. |
baseline and week 12
|
|
Intestinal inflammation
Tidsramme: from baseline to 12 weeks
|
Intestinal barrier integrity as assessed by sCD14 at baseline and at week 12 |
from baseline to 12 weeks
|
|
Intestinal barrier integrity
Tidsramme: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Oxidative stress in blood
Tidsramme: from baseline to 12 weeks
|
Oxidative stress level measured as free thiol content in blood at baseline and at week 12 |
from baseline to 12 weeks
|
|
Inflammatory status in blood
Tidsramme: from baseline to 12 weeks
|
Systemic inflammation measured as high sensitive C reactive protein (hs-CRP) in blood at baseline and at week 12. |
from baseline to 12 weeks
|
|
Gastrointestinal symptoms
Tidsramme: from baseline to 12 weeks
|
Gastrointestinal symptoms as assessed by Gastrointestinal Symptom Rating Scale (GSRS).The GSRS is a 15 items questionnaire combined into five symptom clusters i.e Reflux, Abdominal pain, Indigestion, Diarrhoea and Constipation. The GSRS has a seven-point graded Likert-type scale where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms.(GSRS) at baseline and at week 12. |
from baseline to 12 weeks
|
|
health-related quality of life
Tidsramme: from baseline to 12 weeks
|
Quality of life as assessed by short form survey-36 (SF-36) questionnaires at baseline and at week 12. The SF-36 is a self-administered questionnaire comprising 36-items measuring eight health domains: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). These outcomes will be grouped as a physical component summary and a mental component summary. The norm data is 0-100, and the health-related quality of life increases as the scores increase. |
from baseline to 12 weeks
|
|
Stool consistency
Tidsramme: from baseline to 12 weeks
|
Stool consistency (Bristol Stool Scale), as reported in the daily eDiary app (at baseline and week 12). Participants will identify each bowel movement 'type' using the Bristol Stool Scale (Type 1 = hard stool difficult to pass [classified as severe constipation]; Type 7 = watery, entirely liquid stool [classified as severe diarrhea]). 'Normal' stool is considered to be Types 3 and 4; and Types 6 and 7 would be considered to suggest mild and severe diarrhea, respectively. |
from baseline to 12 weeks
|
|
Stool frequency
Tidsramme: from baseline to 12 weeks
|
Stool frequency, as reported in the daily eDiary app (at baseline and week 12). |
from baseline to 12 weeks
|
|
Systemic vitamin status
Tidsramme: from baseline to 12 weeks
|
The concentration of B vitamins in blood at baseline |
from baseline to 12 weeks
|
|
Faecal physiological pH and redox
Tidsramme: from baseline to 12 weeks
|
Faecal physiological parameters measured as pH and redox potential at baseline and at week 12. |
from baseline to 12 weeks
|
|
Faecal microbial composition at week 4
Tidsramme: from baseline to 4 weeks
|
Faecal microbial composition at phylum, genus, and species levels, as measured by metagenomic based profiles at baseline and at week 4. |
from baseline to 4 weeks
|
|
Alpha diversity at week 4
Tidsramme: baseline to Week 4.
|
Alpha diversity measured as Observed, Chao Index, Simpson Index, Shannon Index at baseline and Week 4. |
baseline to Week 4.
|
|
Beta diversity at week 4
Tidsramme: week 0 to week 4
|
Beta diversity (Jaccard, Bray Curtis, Aitchson) at baseline and week 4 |
week 0 to week 4
|
|
Microbial metabolites at week 4
Tidsramme: from baseline to 4 weeks
|
Faecal microbial metabolites measured as total short-chain fatty acid content at baseline and week 4. |
from baseline to 4 weeks
|
|
Acetate, Propionate and Butyrate at week 4
Tidsramme: week 0 to week 4
|
Acetate, Propionate and Butyrate SCFAs (µmol/g) at baseline and week 4. |
week 0 to week 4
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Skin barrier integrity
Tidsramme: from baseline to 12 weeks
|
Skin barrier integrity measured as trans-epidermal water loss (TEWL) g/m²/h at baseline and at week 12. |
from baseline to 12 weeks
|
|
Skin hydration
Tidsramme: from baseline to 12 weeks
|
Skin hydration measured using corneometry from 0 (no water at all) to 120 (on water) at baseline and at week 12. |
from baseline to 12 weeks
|
|
Objective skin-health
Tidsramme: from baseline to 12 weeks
|
Objective skin-health assessment completed by the participant using Likert scale (from not at al to very much) at baseline and at week 12. |
from baseline to 12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Prof Timothy Dinan, Cork University Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2020-11-11-VITB2
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .